Daniel Todt
Overview
Explore the profile of Daniel Todt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
2289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wissing M, Meister T, Nocke M, Gomer A, Masovic M, Knegendorf L, et al.
Nat Commun
. 2024 Jun;
15(1):4855.
PMID: 38844458
Hepatitis E virus (HEV) is a long-neglected RNA virus and the major causative agent of acute viral hepatitis in humans. Recent data suggest that HEV has a very heterogeneous hypervariable...
12.
Jagst M, Gomer A, Todt D, Steinmann E
Antiviral Res
. 2024 Jun;
227:105922.
PMID: 38825018
Hepatitis E is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic, but can reach mortality rates up to 25%...
13.
Qu B, Miskey C, Gomer A, Kleinert R, Ibanez S, Eberle R, et al.
Proc Natl Acad Sci U S A
. 2024 May;
121(23):e2407437121.
PMID: 38814864
The accessory protease transmembrane protease serine 2 (TMPRSS2) enhances severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uptake into ACE2-expressing cells, although how increased entry impacts downstream viral and host processes...
14.
Klohn M, Burkard T, Janzen J, Haase J, Gomer A, Fu R, et al.
Hepatology
. 2024 May;
80(5):1239-1251.
PMID: 38728662
Background And Aims: HEV is estimated to be responsible for 70,000 deaths annually, yet therapy options remain limited. In the pursuit of effective antiviral therapies, targeting viral entry holds promise...
15.
Plumers R, Dreier J, Knabbe C, Steinmann E, Todt D, Vollmer T
Emerg Infect Dis
. 2024 Apr;
30(5):934-940.
PMID: 38666600
To determine the kinetics of hepatitis E virus (HEV) in asymptomatic persons and to evaluate viral load doubling time and half-life, we retrospectively tested samples retained from 32 HEV RNA-positive...
16.
Konkol J, Becker B, Paulmann D, Steinmann E, Todt D, Meister T, et al.
J Appl Microbiol
. 2024 Mar;
135(3).
PMID: 38439676
Aims: We aimed to develop a method to assess the virucidal performance of domestic laundry in a lab-scale washing machine (Rotawash) based on EN 17658. Methods And Results: For method...
17.
Gomer A, Dinkelborg K, Klohn M, Jagst M, Wissing M, Frericks N, et al.
JHEP Rep
. 2024 Mar;
6(3):100989.
PMID: 38434938
Background & Aims: In the absence of a hepatitis E virus (HEV)-specific antiviral treatment, sofosbuvir has recently been shown to have antiviral activity against HEV . However, a variant, A1343V,...
18.
Frericks N, Brown R, Reinecke B, Herrmann M, Bruggemann Y, Todt D, et al.
J Virol
. 2024 Feb;
98(3):e0192123.
PMID: 38319104
Importance: Hepatitis C virus (HCV) infection remains a global health burden with 58 million people currently chronically infected. However, the detailed molecular mechanisms that underly persistence are incompletely defined. We...
19.
Rau F, Elsner C, Meister T, Gomer A, Kallies R, Dittmer U, et al.
Liver Int
. 2024 Jan;
44(3):637-643.
PMID: 38291853
Hepatitis E virus (HEV) is prevalent worldwide and can cause persistent infection with severe morbidity. Antiviral treatment approaches can lead to the emergence of viral variants encoding escape mutations that...
20.